Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07284849 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 280 → 293 locations
  2. Trial sites expanded: 254 → 280 locations Eligibility criteria expanded, about 13 words · Secondary endpoints: details revised at 4 of 8 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 4 of 8 entries
  3. Study sites: 255 to 254v18
  4. Study sites: 254 to 255v17
  5. Trial sites reduced: 276 → 254 locationsv16
Show 6 earlier versionsHide 6 earlier versions
  1. Study sites: 275 to 276v15
  2. Study sites: 274 to 275v14
  3. Study sites revised (274)v13 See this version in full on ClinicalTrials.gov ↗
  4. Study sites: 273 to 274v12
  5. Re-verified, no change to tracked fieldsv11
  6. Study sites: 272 to 273v10
  1. Trial sites expanded: 249 → 272 locations Study sites revised (272)v9 Show 1 more changeShow less
    • Study sites revised (272)

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 249 to 272v8
  3. Study sites: 248 to 249v7
  4. Study sites: 240 to 248v6
  5. Study sites: 234 to 240v5
  6. Study sites: 197 to 234 Start date changed from estimate of Feb 16, 2026 to Mar 5, 2026v4 Show 1 more changeShow less
    • Start date changed from estimate of Feb 16, 2026 to Mar 5, 2026
  7. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 197v3 Show 1 more changeShow less
    • Study sites: 0 to 197
  8. Study Status, Referencesv2
  9. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Incyte
94 trials monitored
See 9 trials at risk
Colorectal Cancer
2,920 trials monitored
See 132 trials at risk
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
Trial Details
NCT Number NCT07284849
Lead Sponsor Incyte Corporation
Conditions CRC (Colorectal Cancer)
Enrollment 700 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov